Notice: This company has been marked as potentially delisted and may not be actively trading. Conatus Pharmaceuticals (CNAT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends CNAT vs. INM, SBFM, BPTH, LIPO, OGEN, ZVSA, HEPA, RSLS, KTTA, and PTIXShould you be buying Conatus Pharmaceuticals stock or one of its competitors? The main competitors of Conatus Pharmaceuticals include InMed Pharmaceuticals (INM), Sunshine Biopharma (SBFM), Bio-Path (BPTH), Lipella Pharmaceuticals (LIPO), Oragenics (OGEN), ZyVersa Therapeutics (ZVSA), Hepion Pharmaceuticals (HEPA), ReShape Lifesciences (RSLS), Pasithea Therapeutics (KTTA), and Protagenic Therapeutics (PTIX). These companies are all part of the "medical" sector. Conatus Pharmaceuticals vs. InMed Pharmaceuticals Sunshine Biopharma Bio-Path Lipella Pharmaceuticals Oragenics ZyVersa Therapeutics Hepion Pharmaceuticals ReShape Lifesciences Pasithea Therapeutics Protagenic Therapeutics Conatus Pharmaceuticals (NASDAQ:CNAT) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment. Is CNAT or INM more profitable? Conatus Pharmaceuticals has a net margin of -52.42% compared to InMed Pharmaceuticals' net margin of -137.41%. Conatus Pharmaceuticals' return on equity of -48.22% beat InMed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Conatus Pharmaceuticals-52.42% -48.22% -39.32% InMed Pharmaceuticals -137.41%-65.74%-53.57% Does the MarketBeat Community prefer CNAT or INM? Conatus Pharmaceuticals received 529 more outperform votes than InMed Pharmaceuticals when rated by MarketBeat users. Likewise, 79.67% of users gave Conatus Pharmaceuticals an outperform vote while only 47.06% of users gave InMed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformConatus PharmaceuticalsOutperform Votes53779.67% Underperform Votes13720.33% InMed PharmaceuticalsOutperform Votes847.06% Underperform Votes952.94% Do institutionals and insiders hold more shares of CNAT or INM? 15.2% of Conatus Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 11.3% of Conatus Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of InMed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has preferable earnings & valuation, CNAT or INM? InMed Pharmaceuticals has lower revenue, but higher earnings than Conatus Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConatus Pharmaceuticals$21.72M0.04-$11.39MN/AN/AInMed Pharmaceuticals$4.96M0.58-$7.68M-$13.91-0.29 Does the media refer more to CNAT or INM? In the previous week, InMed Pharmaceuticals had 5 more articles in the media than Conatus Pharmaceuticals. MarketBeat recorded 5 mentions for InMed Pharmaceuticals and 0 mentions for Conatus Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.26 beat Conatus Pharmaceuticals' score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Conatus Pharmaceuticals Neutral InMed Pharmaceuticals Neutral Which has more volatility & risk, CNAT or INM? Conatus Pharmaceuticals has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. SummaryConatus Pharmaceuticals beats InMed Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Get Conatus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNAT vs. The Competition Export to ExcelMetricConatus PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$929,000.00$6.55B$5.39B$9.24BDividend YieldN/A2.96%5.37%3.99%P/E Ratio-0.099.8989.1117.52Price / Sales0.04334.961,229.3683.37Price / CashN/A64.1243.6036.96Price / Book0.055.105.014.72Net Income-$11.39M$154.66M$117.81M$224.61M Conatus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNATConatus PharmaceuticalsN/A$0.03+3.7%N/A-92.6%$929,000.00$21.72M-0.0930Gap UpINMInMed Pharmaceuticals0.8665 of 5 stars$4.95+10.0%N/A-42.9%$3.56M$4.60M-0.3610News CoveragePositive NewsHigh Trading VolumeSBFMSunshine Biopharma2.0909 of 5 stars$2.90+2.5%$15.00+417.2%-87.5%$3.54M$24.09M-0.023BPTHBio-Path1.4166 of 5 stars$0.82+0.7%$20.00+2,339.0%-89.4%$3.53MN/A0.0010LIPOLipella Pharmaceuticals2.4263 of 5 stars$2.85-2.4%$16.00+461.4%-62.9%$3.45M$450,000.00-0.674News CoverageNegative NewsOGENOragenicsN/A$0.28-5.4%N/AN/A$3.44M$40,000.00-0.045Analyst ForecastNews CoverageZVSAZyVersa Therapeutics3.1496 of 5 stars$1.42+5.2%$120.00+8,350.7%-75.7%$3.32MN/A0.002HEPAHepion Pharmaceuticals0.4315 of 5 stars$0.47+4.2%N/A-93.5%$3.26MN/A-0.1120News CoveragePositive NewsRSLSReShape Lifesciences0.4336 of 5 stars$4.52-3.2%N/A-66.8%$3.22M$8.18M0.0050Gap UpKTTAPasithea Therapeutics0.9554 of 5 stars$2.48+1.2%N/A-64.9%$3.15MN/A0.003PTIXProtagenic Therapeutics0.4779 of 5 stars$0.44-2.0%N/A-55.1%$3.13MN/A-0.352Negative News Related Companies and Tools Related Companies InMed Pharmaceuticals Competitors Sunshine Biopharma Competitors Bio-Path Competitors Lipella Pharmaceuticals Competitors Oragenics Competitors ZyVersa Therapeutics Competitors Hepion Pharmaceuticals Competitors ReShape Lifesciences Competitors Pasithea Therapeutics Competitors Protagenic Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CNAT) was last updated on 1/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conatus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Conatus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNAT Stock Alerts